Rothschild Investment Corp Editas Medicine, Inc. Transaction History

Rothschild Investment Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 25, 2021	SELL	$27.07 - $84.35 $217,913 - $679,017	-8,050 Closed	0 $0
Q3 2020 Oct 22, 2020	SELL	$28.06 - $37.16 $8,418 - $11,147	-300 Reduced 3.59%	8,050 $226,000
Q2 2020 Jul 24, 2020	BUY	$18.5 - $34.34 $154,475 - $286,739	8,350 New	8,350 $247,000
Q1 2020 Apr 16, 2020	SELL	$14.88 - $32.78 $136,152 - $299,937	-9,150 Closed	0 $0
Q4 2019 Jan 22, 2020	SELL	$19.49 - $32.63 $3,897 - $6,526	-200 Reduced 2.14%	9,150 $271,000
Q4 2018 Jan 28, 2019	SELL	$18.19 - $31.79 $3,638 - $6,358	-200 Reduced 2.09%	9,350 $213,000
Q3 2018 Oct 17, 2018	BUY	$27.65 - $38.39 $5,530 - $7,678	200 Added 2.14%	9,550 $304,000
Q2 2018 Jul 24, 2018	BUY	$31.4 - $41.01 $53,380 - $69,717	1,700 Added 22.22%	9,350 $335,000
Q1 2018 Apr 27, 2018	SELL	$29.84 - $44.08 $26,856 - $39,672	-900 Reduced 10.53%	7,650 $254,000
Q4 2017 Jan 23, 2018	BUY	$21.89 - $31.34 $187,159 - $267,957	8,550	8,550 $263,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $151M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Rothschild Investment Corp , based on Form 13F filings with the SEC.

Stay updated on Rothschild Investment Corp with notifications on news.